Employers have spent the past two years expanding access to weight-loss treatment. A new survey suggests many of them stop there. The poll was conducted by The Harris Poll on behalf of Wondr Health, a company that sells weight management programs to employers.
Only one in four Americans with employer-sponsored benefits who recently pursued weight loss received ongoing support to help maintain it, according to a national poll conducted by The Harris Poll on behalf of Wondr Health. The survey, fielded September 22 and 23, covered 2,012 US adults, of whom 1,270 reported having employer-sponsored health benefits and a recent weight-loss journey.
The finding comes as employers face growing pressure to justify their weight management spending. Among firms with 5,000 or more workers, GLP-1 coverage for weight loss climbed from 28% in 2024 to 43% in 2025, according to the KFF 2025 Employer Health Benefits Survey. The costs that come with that expansion are already prompting some to pull back, and the case for staying in becomes harder to make if the clinical gains don’t hold.
The maintenance gap in employer benefits runs up against a well-established pattern in the clinical literature. A meta-analysis of 29 long-term weight loss studies, published in Medical Clinics of North America in 2018, found that more than half of lost weight is typically regained within two years, and more than 80% within five years.
That trajectory applies to weight loss from conventional interventions. GLP-1 medications add a specific wrinkle. A systematic review and meta-analysis published in The BMJ in January 2026, drawing on 37 studies covering more than 9,300 participants, found that patients who stopped semaglutide or tirzepatide regained roughly two-thirds of their prior weight loss within a year, with return to near-baseline weight projected within approximately 18 months.
A 2024 randomized controlled trial published in eClinicalMedicine found that patients who combined GLP-1 therapy with supervised exercise regained significantly less weight in the year after stopping treatment than those who received GLP-1 therapy alone, six kilograms less on average. An employer benefit that funds the treatment but not the maintenance period is, in structural terms, paying for the front end of a cycle that frequently reverses.
“Losing weight is only the first step,” said Tim Church, chief medical officer of Wondr Health. “Keeping it off requires ongoing, structured support to build and reinforce healthy behaviors over time, yet few people are getting that support through their benefits.”
The survey arrives as employers are finalizing 2027 benefit designs. Eighty-one percent of survey respondents said they believe employer-sponsored health benefits should help people maintain weight loss, not just access treatment. That figure reflects employee expectations heading into the next renewal cycle.
Benefits advisors working through GLP-1 coverage decisions with clients are already navigating a more complex question than access alone. Recent employer-level research on GLP-1 outcomes has sharpened the focus on which patients are most likely to benefit from treatment, and that same framework applies to maintenance. A program that identifies effective responders but doesn’t support them through the high-risk regain period is only partially designed.
The survey does not resolve what maintenance support looks like in practice, or what it costs. But the finding gives advisors a reference point heading into 2027 renewals. Three in four workers who recently used employer benefits for weight loss received no follow-on support.
